Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Learn more in this guide
Labels After reconstitution, label your vial with the date, the concentration (mg/mL), and the contents
W.HorngS.et al (2018)
In January 2025, Metsera, a New York-based obesity healthcare company, announced positive topline results from its Phase IIa clinical trial for MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA)
Works through GLP-1 pathway (independent of thyroid) Reduces appetite that thyroid medication can't control Improves insulin sensitivity (often impaired with hypothyroidism) Safe to use alongside levothyroxine and other thyroid medications Beyond "Normal" TSH: Optimizing Your Treatment Many hypothyroid patients are told their TSH is "normal"but normal isn't optimal
Protocol compliance: Consistent administration and proper reconstitution affect outcomes
